The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Abstract Background Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between BRCA1-like and non-BRCA1-like tumors. We hypothesized that these tumors may also be more sensitive...

Full description

Bibliographic Details
Main Authors: Tesa M. Severson, Denise M. Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C. Schouten, Suet-Feung Chin, Ian J. Majewski, Magali Michaut, Astrid Bosma, Bernard Pereira, Tycho Bismeijer, Lodewyk Wessels, Carlos Caldas, René Bernards, Iris M. Simon, Annuska M. Glas, Sabine Linn, Laura van ‘t Veer
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Neoadjuvant
BRCAness
PARP inhibition
Triple-negative breast cancer
Online Access:http://link.springer.com/article/10.1186/s13058-017-0861-2

Internet

http://link.springer.com/article/10.1186/s13058-017-0861-2

Similar Items